Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMBRACE-STEMI: Elamipretide for Reperfusion Injury
NCT01572909Phase 2Completed
- Sponsor
- Stealth BioTherapeutics
- Start
- Apr 2012
- Primary completion
- Nov 2014
- Modality
- Peptides, Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of elamipretide in reperfusion injury (IRI), sponsored by Stealth BioTherapeutics. Started Apr 2012; status: completed.
02
Drugs
elamipretide
03
Conditions
reperfusion injury (IRI)
Beyond the preview
Go deeper on NCT01572909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01572909.